The federal government is releasing millions of Moderna booster shots that were delayed by the Food and Drug Administration as a result of a safety inspection at an Indiana packaging plant, even as states report shortages and encourage people to get Pfizer boosters instead.
The new, updated COVID-19 vaccines are designed to protect against the version of Omicron that is dominant in the U.S. and around the world.— The White House (@WhiteHouse) September 16, 2022
Watch as White House COVID-19 Response Coordinator Dr. Jha explains why everyone should get an updated COVID vaccine this fall: pic.twitter.com/qJVYrsFuih
The FDA’s inspection was focused on production issues at a plant in Bloomington, Ind., operated by Catalent, which is helping to bottle and package Moderna’s vaccine. Inspectors last month began raising concerns that the facility was not sufficiently sterile and started checking whether vials packaged there might have been contaminated, as part of routine safety reviews, said people with knowledge of the inspection. FDA inspectors concluded that there were no problems with Moderna’s vaccine, and the agency is set to soon release more than 10 million doses that had been held back.
“On Tuesday, FDA authorized distribution of numerous batches of the updated Moderna COVID-19 Vaccine, Bivalent booster manufactured at Catalent’s facility,” FDA spokesperson Michael Felberbaum said in a statement. “This authorization was based on FDA’s determination that the batches met all applicable specifications, following a careful review of information provided by Moderna about the manufacture of these batches. The agency has no concerns with the safety, effectiveness, or quality of these batches.”
FDA inspectors found no safety issues at a second plant, operated by Thermo Fisher Scientific, which is also working to help finish Moderna’s vaccines for U.S. distribution, officials said.
In a statement, Moderna said it was “working closely” with the government to deliver additional doses of its bivalent booster shots — which include components aimed at the latest subvariants as well as the original virus identified in China that has long since disappeared — amid “high demand” in parts of the country.
“We anticipate that these availability constraints will be resolved in the coming days,” spokesperson Chris Ridley said. “We continue to be on track to meet our committed delivery of 70 million doses of our updated, bivalent vaccine by the end of this year.”
The FDA on Aug. 31 authorized new omicron-targeting coronavirus booster shots from Moderna and Pfizer, with experts saying the shots should improve protection against severe illness and death during a potential increase in covid-19 cases this fall and winter. But providers around the country have reported shortages of Moderna in recent weeks, prompting state officials to encourage consumers to seek out the alternative.
“If your provider is waiting for Moderna Omicron booster doses, there’s plenty of Pfizer,” Don Herrington, interim director of the Arizona Department of Health Services, wrote in a blog post on Monday. Herrington said federal officials advised that the supply issues would be resolved “in approximately two weeks.”
FDA officials first became aware of potential safety concerns at the Catalent plant in late August, even as the agency was preparing to authorize the new boosters, said three people with knowledge of the inspection who spoke on the condition of anonymity because they were not authorized to comment. Biden officials have avoided publicly commenting on the Moderna booster delays until the safety inspection was complete amid concerns about undermining vaccine confidence, the people said.
According to the FDA, the agency did not initially include the Catalent facility when authorizing the booster shots because of the ongoing safety inspection.
Chris Halling, a spokesperson for Catalent, said in a statement Tuesday evening: “A recent FDA inspection at our Bloomington facility resulted in observations that Catalent is already addressing, as it seeks to continuously improve its operations. Production at the facility has continued without interruption.”
In interviews this month, Biden officials said the holdup with Moderna shots would not significantly constrain short-term supply for the booster campaign, since they had already planned to rely on the shots produced by Pfizer and its German partner, BioNTech. The administration this year ordered more than twice as many doses from Pfizer-BioNTech than Moderna for the booster campaign.
It’s unclear whether some patients have a preference for the Moderna shots, said Marcus Plescia, chief medical officer for the Association of State and Territorial Health Officials. “It appears there are adequate supplies of Pfizer to meet current demand,” Plescia added, though he said he was still gathering information from state officials.
The FDA inspection was another wrench in the vaccine production process, an issue that occurs with some frequency in the pharmaceutical industry. Problems at a Baltimore plant operated by Emergent, another contract manufacturer, halted production of the Johnson & Johnson coronavirus vaccine there last year and prompted government officials to discard millions of doses. Catalent’s Indiana plant had also been faulted by FDA inspectors in a 2018 inspection that found problems with quality control.
Public health experts also expressed concern that Biden’s remark on “60 Minutes,” which aired Sunday, could be another factor dampening enthusiasm for the booster campaign. While the president acknowledged that the nation “still [has] a problem with covid,” his assertion that the pandemic is over was widely amplified, including by Republicans who asked why the White House is continuing to promote vaccination campaigns if the threat has receded.
“It was an uphill battle already,” said Jennifer Kates, who leads global health policy for the Kaiser Family Foundation, a nonpartisan think tank. “There’s still messaging confusion. People are unclear if they should get a new booster, when should they get the booster … [it’s] a very difficult landscape of trying to help the public understand that these vaccines are safe and effective.”
Kates said she encountered the Moderna shortage recently when she went for a booster shot. “If there are people who have a preference, that’s a wrinkle to them,” she said.
The White House on Tuesday maintained that Biden’s comments on “60 Minutes” were consistent with the administration’s posture that covid deaths and severe illness have come down — and can be further reduced with vaccination.
“We know the tools that are out there to fight covid,” White House press secretary Karine Jean-Pierre said at a briefing Tuesday.
Coronavirus: What you need to know
The latest: The CDC has loosened many of its recommendations for battling the coronavirus, a strategic shift that puts more of the onus on individuals, rather than on schools, businesses and other institutions, to limit viral spread.
Variants: BA.5 is the most recent omicron subvariant, and it’s quickly become the dominant strain in the U.S. Here’s what to know about it, and why vaccines may only offer limited protection.
Vaccines: Vaccines: The Centers for Disease Control and Prevention recommends that everyone age 12 and older get an updated coronavirus booster shot designed to target both the original virus and the omicron variant circulating now. You’re eligible for the shot if it has been at least two months since your initial vaccine or your last booster. An initial vaccine series for children under 5, meanwhile, became available this summer. Here’s what to know about how vaccine efficacy could be affected by your prior infections and booster history.
Guidance: CDC guidelines have been confusing — if you get covid, here’s how to tell when you’re no longer contagious. We’ve also created a guide to help you decide when to keep wearing face coverings.
For the latest news, sign up for our free newsletter.